Klapheke Amy, Yap Stanley A, Pan Kevin, Cress Rosemary D
Public Health Institute, Cancer Registry of Greater California, Sacramento, CA; Department of Public Health Sciences, University of California Davis, Davis, CA.
Department of Urology, University of California Davis, Sacramento, CA; University of California Davis Comprehensive Cancer Center, Sacramento, CA.
Urol Oncol. 2018 Jun;36(6):308.e19-308.e25. doi: 10.1016/j.urolonc.2018.03.008. Epub 2018 Apr 5.
To evaluate how socioeconomic status and other demographic factors are associated with the receipt of chemotherapy and subsequent survival in patients diagnosed with metastatic bladder cancer.
Using data from the California Cancer Registry, we identified 3,667 patients diagnosed with metastatic urothelial carcinoma of the urinary bladder between 1988 and 2014. The characteristics of patients who did and did not receive chemotherapy as part of the first course of treatment were compared using chi-square tests. Logistic regression was used to identify predictors of chemotherapy treatment. Fine and Gray competing-risks regression and Cox proportional hazards regression were used to estimate bladder cancer-specific and all-cause mortality, respectively.
Less than half (46.3%) of patients received chemotherapy. Patients from the lowest socioeconomic quintile were half as likely to have chemotherapy as those from highest quintile (odds ratio = 0.5, 95% CI: 0.4, 0.7). Unmarried patients were significantly less likely to receive treatment (odds ratio = 0.6, 95% CI: 0.5, 0.7). Not receiving chemotherapy was associated with greater mortality from bladder cancer (subdistribution hazard ratio = 1.4, 95% CI: 1.3, 1.5) and from all causes (hazard ratio = 2.0, 95% CI: 1.8, 2.1).
We found clear disparities in chemotherapy treatment and survival with respect to socioeconomic and marital status. Future studies should explore the possible reasons why patients with low socioeconomic status and who are unmarried are less likely to have chemotherapy.
评估社会经济地位和其他人口统计学因素与转移性膀胱癌患者接受化疗及后续生存情况之间的关联。
利用加利福尼亚癌症登记处的数据,我们确定了1988年至2014年间被诊断为转移性膀胱尿路上皮癌的3667例患者。使用卡方检验比较了接受和未接受化疗作为第一疗程治疗一部分的患者特征。采用逻辑回归来确定化疗治疗的预测因素。分别使用Fine和Gray竞争风险回归以及Cox比例风险回归来估计膀胱癌特异性死亡率和全因死亡率。
不到一半(46.3%)的患者接受了化疗。社会经济地位最低五分位数的患者接受化疗的可能性仅为最高五分位数患者的一半(优势比 = 0.5,95%置信区间:0.4,0.7)。未婚患者接受治疗的可能性显著较低(优势比 = 0.6,95%置信区间:0.5,0.7)。未接受化疗与膀胱癌更高的死亡率(亚分布风险比 =